FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to therapy and endocrinology, and can be used to treat diabetic foot syndrome. For this purpose, a biomedical cell product is introduced, the cell line comprising which has a CD marker selected from the group consisting of CD73, CD106, CD146, CD200, CD271, and the cells as part of which are administered in a dose of 10 to 50 thousand skin cells/cm2.
EFFECT: method allows to increase the effectiveness of treatment of diabetic foot syndrome when using low doses of cells due to their accurate marker verification.
3 cl, 3 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SOFT TISSUES DEFECTS TREATMENT IN PATIENTS WITH DIABETIC FOOT SYNDROME | 2016 |
|
RU2619257C1 |
| MEDICINAL PRODUCT FOR THE TREATMENT OF ULCER DEFECTS IN "DIABETIC FOOT" SYNDROME | 2023 |
|
RU2804781C1 |
| METHOD FOR GENE THERAPY TREATMENT OF DIABETIC FOOT SYNDROME | 2015 |
|
RU2599507C1 |
| METHOD FOR TREATMENT OF UNINFECTED POSTOPERATIVE WOUND DEFECT OF THE FOOT IN THE ABSENCE OF SIGNS OF CRITICAL LIMB ISCHEMIA IN PATIENTS WITH NEUROPATHIC AND NEUROISCHEMIC FORMS OF DIABETIC FOOT SYNDROME | 2020 |
|
RU2754383C1 |
| METHOD OF TREATING DEFECTS OF SKIN AND SOFT TISSUES IN PATIENTS WITH DIABETES MELLITUS AND METHOD OF INTRODUCTION OF DRUG THEREFOR | 2017 |
|
RU2679449C1 |
| EXTRACELLULAR VESICLES ORIGINATING FROM MESENCHYMAL STEM CELLS | 2019 |
|
RU2805066C2 |
| METHOD OF TREATING NEUROPATHIC TROPHIC ULCERS ACCOMPANYING DIABETIC FOOT | 2013 |
|
RU2549459C2 |
| METHOD FOR TREATING DIABETIC FOOT SYNDROME BEFORE FORMATION OF ULCEROUS DEFECT USING EXTRACORPORAL SHOCK WAVE THERAPY | 2016 |
|
RU2632683C1 |
| METHOD FOR PERSONALISING THERAPY OF AN ULCEROUS DEFECT IN DIABETIC FOOT SYNDROME | 2021 |
|
RU2785531C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH CONGENITAL EPIDERMOLYSIS BULLOSA BY COMBINED USE OF HUMAN ALLOGENEIC FIBROBLASTS AND LIVING SKIN EQUIVALENT | 2020 |
|
RU2779997C2 |
